Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review

The mRNA therapeutics have been studied since the 1970s and the currently available mRNA vaccines against COVID-19 are the culmination of decades of scientific research. The mRNA vaccines BNT162b2 and mRNA-1273 have played a key role in our global response to the COVID-19 pandemic as they have demon...

Descripción completa

Detalles Bibliográficos
Autores principales: Akamine, Christine M., El Sahly, Hana M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695521/
https://www.ncbi.nlm.nih.gov/pubmed/34954088
http://dx.doi.org/10.1016/j.trsl.2021.12.007
_version_ 1784619597626867712
author Akamine, Christine M.
El Sahly, Hana M.
author_facet Akamine, Christine M.
El Sahly, Hana M.
author_sort Akamine, Christine M.
collection PubMed
description The mRNA therapeutics have been studied since the 1970s and the currently available mRNA vaccines against COVID-19 are the culmination of decades of scientific research. The mRNA vaccines BNT162b2 and mRNA-1273 have played a key role in our global response to the COVID-19 pandemic as they have demonstrated significant advantages over conventional vaccines and have proven to be highly effective against COVID-19 associated hospitalization and severe illness in large clinical trials and studies using real-world data.
format Online
Article
Text
id pubmed-8695521
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-86955212021-12-23 Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review Akamine, Christine M. El Sahly, Hana M. Transl Res Review Article The mRNA therapeutics have been studied since the 1970s and the currently available mRNA vaccines against COVID-19 are the culmination of decades of scientific research. The mRNA vaccines BNT162b2 and mRNA-1273 have played a key role in our global response to the COVID-19 pandemic as they have demonstrated significant advantages over conventional vaccines and have proven to be highly effective against COVID-19 associated hospitalization and severe illness in large clinical trials and studies using real-world data. Elsevier Inc. 2022-04 2021-12-23 /pmc/articles/PMC8695521/ /pubmed/34954088 http://dx.doi.org/10.1016/j.trsl.2021.12.007 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Article
Akamine, Christine M.
El Sahly, Hana M.
Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review
title Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review
title_full Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review
title_fullStr Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review
title_full_unstemmed Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review
title_short Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review
title_sort messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695521/
https://www.ncbi.nlm.nih.gov/pubmed/34954088
http://dx.doi.org/10.1016/j.trsl.2021.12.007
work_keys_str_mv AT akaminechristinem messengerribonucleicacidvaccinesforsevereacuterespiratorysyndromecoronavirus2areview
AT elsahlyhanam messengerribonucleicacidvaccinesforsevereacuterespiratorysyndromecoronavirus2areview

Ejemplares similares